Whalesbook
Accretion Nutraveda Ltd. reported a strong financial performance for fiscal year 2026. Audited results show revenue more than doubling to ₹33.60 crore from ₹16.00 crore in FY25. Net profit after tax also surged 102% to ₹5.07 crore, up from ₹2.50 crore in the prior year. The company also confirmed the re-appointment of secretarial auditors and the appointment of new internal auditors for FY27.
Alongside these financial results, Accretion Nutraveda announced changes to its board composition. Two independent directors have resigned, with the company citing personal reasons. The board plans to appoint two new directors, a move that will be subject to shareholder approval and could reshape the board's expertise and strategic oversight.
A key focus for investors remains the deployment of capital raised through the company's Initial Public Offering (IPO). Accretion Nutraveda raised ₹24.76 crore in its IPO, which listed on the BSE on February 4, 2026, with funds earmarked for working capital and capital expenditure. As of March 31, 2026, ₹655.48 lakh of these proceeds remained unutilized, currently held in short-term deposits. The effective deployment of these funds is seen as crucial for driving future growth.
Investors will be looking to the upcoming shareholder meeting for the approval of the new directors. They will also closely monitor the company's progress in finalizing and executing plans for the substantial unutilized IPO capital. Future quarterly results will be important for assessing the sustainability of Accretion Nutraveda's strong revenue and profit growth momentum.